AZTR

8-K - Azitra, Inc. (0001701478) (Filer)

BRANFORD, Conn., Aug. 21, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and high value cosmetic proteins and peptides, today announced that it has received written notification from NYSE American LLC ("NYSE American") confirming that the Company has regained compliance with all of the NYSE American continued listing standards set forth in Part 10 of the NYSE American Company Guide. In a letter dated August 19, 2026, NYSE Regulation informed Azitra that the Company has resolved the previous

SCHEDULE 13G - Azitra, Inc. (0001701478) (Subject)

SCHEDULE 13G - Azitra, Inc. (0001701478) (Subject)

BRANFORD, Conn., Aug. 12, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and high value cosmetic proteins and peptides, today reported financial results for the quarter ended June 30, 2026, and provided a business update. Q2 2026 and Recent Business HighlightsReported the first preclinical data from ATR-COSF demonstrating breakthrough repeat-dose distribution, controlled delivery into targeted skin layers and anti-wrinkle activity in ex vivo human skin, supporting advancement toward a plann

8-K - Azitra, Inc. (0001701478) (Filer)

10-Q - Azitra, Inc. (0001701478) (Filer)

8-K - Azitra, Inc. (0001701478) (Filer)

In the news release, Azitra, Inc. Announces Breakthrough Repeat Dose and Anti-Wrinkle Ex Vivo Results for ATR-COSF Program, Demonstrating Increased Distribution and Elasticity, issued 15-Jul-2026 by Azitra, Inc. over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end: Azitra, Inc. Announces Breakthrough Repeat Dose and Anti-Wrinkle Ex Vivo Results for ATR-COSF Program, Demonstrating Increased Distribution and Elasticity ATR-COSF uses a supernatant based formulation containing an active recombinant human domain of the protein, filaggrin ("rHDfilaggrin"). This S. epidermis derived supernatant is in

ATR-COSF uses a supernatant based formulation containing an active recombinant human domain of the protein, filaggrin ("rHDfilaggrin"). This S. epidermis derived supernatant is in development as a high value cosmetic ingredientEx vivo data successfully showed controlled distribution of the rHDfilaggrin into the stratum granulosum in increased amounts over prior single dose experiments in human skin Single dose ex vivo experiments established improvements in elasticity and reduced the appearance of new fine lines and wrinkles in human skin BRANFORD, Conn., July 15, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therap

SCHEDULE 13G - Azitra, Inc. (0001701478) (Subject)

4 - Azitra, Inc. (0001701478) (Issuer)

8-K - Azitra, Inc. (0001701478) (Filer)

BRANFORD, Conn., June 17, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that Francisco Salva, Chief Executive Officer of Azitra, has issued a Letter to Shareholders detailing the Company's strategic growth initiatives, recent accomplishments and outlook for 2026 and beyond. The full text of the letter follows. A MESSAGE FROM OUR CHIEF EXECUTIVE OFFICERTo my fellow shareholders,The first half of 2026 signaled an important inflection point in Azitra's history. During this pe

BRANFORD, Conn., June 16, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that Cofounder and Chief Operating Officer, Travis Whitfill Ph.D., MPH, will present at BIO International Convention, being held June 22-25, 2026, in San Diego, California. The presentation will highlight recent updates and progress in Azitra's pipeline, including the launch of an innovative protein and peptide program for the cosmetic and cosmeceutical markets leveraging proprietary filaggrin technologies.Presentation Details:Ev

8-K - Azitra, Inc. (0001701478) (Filer)

DEFA14A - Azitra, Inc. (0001701478) (Filer)

8-K - Azitra, Inc. (0001701478) (Filer)

BRANFORD, Conn., June 4, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced its 2026 Annual Meeting, originally scheduled for and convened on June 4, 2026, has been adjourned until June 15, 2026, at 11:00 a.m. Eastern Time, because the Company did not have a sufficient number of shares of the Company's common stock present virtually or represented by proxy at the 2026 Annual Meeting to constitute a quorum and to provide stockholders additional time to review the proxy materials and vote at the 2026 Annual Meeting on the proposals outlined below and described in the Com

EFFECT - Azitra, Inc. (0001701478) (Filer)

DEFA14A - Azitra, Inc. (0001701478) (Filer)

8-K - Azitra, Inc. (0001701478) (Filer)

BRANFORD, Conn., May 27, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it intends to convene its upcoming 2026 annual meeting of stockholders (the "2026 Annual Meeting") scheduled for June 4, 2026 at 11:00 a.m., Eastern Time, and then immediately adjourn proceedings, without conducting any other business. Azitra intends to reconvene the 2026 Annual Meeting on June 15, 2026 at 11:00 a.m., Eastern Time (the "Reconvened 2026 Annual Meeting"). The Company has determined to adjourn the 2026 Annual Meeting to allow additional time for stockholders to receive and su

S-1 - Azitra, Inc. (0001701478) (Filer)

BRANFORD, Conn., May 13, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the quarter ended March 31, 2026, and provided a business update. Q1 2026 and Recent Business HighlightsAnnounced the addition of MD Anderson Cancer Center as a clinical site for Phase 1/2 trial of ATR-04 targeting EGFRi-associated skin rash.Launched innovative protein and peptide programs for the cosmetic and cosmeceutical markets l